U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H18N2
Molecular Weight 310.3917
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIFONAZOLE

SMILES

C1=CN(C=N1)C(C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=CC=C4

InChI

InChIKey=OCAPBUJLXMYKEJ-UHFFFAOYSA-N
InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H

HIDE SMILES / InChI
Bifonazole, a substituted imidazole, is a broad-spectrum antimycotic, interferes with sterol biosynthesis. Bifonazole possesses a sequential mode of action, namely inhibition of cytochrome P450-dependent C14-demethylation of sterols and direct inhibition of HMG-CoA-reductase. It possesses a broad spectrum of activity in vitro against dermatophytes, moulds, yeasts, dimorphic fungi and some Gram-positive bacteria. Bifonazole is an effective and well-tolerated treatment for superficial fungal infections of the skin.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BIFONAZOLE

Approved Use

Bifonazole Cream is used to treat fungal skin infections such as ringworm, athlete’s foot and fungal sweat rash. The active substance in Canesten Bifonazole Cream is bifonazole. Bifonazole belongs to a group of medicines called imidazoles and is an antifungal agent which fights the cause of fungal skin infections.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1 ng/mL
15.2 mg single, transdermal
dose: 15.2 mg
route of administration: Transdermal
experiment type: SINGLE
co-administered:
BIFONAZOLE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.4 ng/mL
15.2 mg single, transdermal
dose: 15.2 mg
route of administration: Transdermal
experiment type: SINGLE
co-administered:
BIFONAZOLE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Seborrhoeic dermatitis.
2010-12-07
Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation.
2010-08-02
Prevention and treatment of intertrigo in large skin folds of adults: a systematic review.
2010-07-13
A New Validated HPLC Method for the Simultaneous Determination of 2-phenoxyethanol, Methylparaben, Ethylparaben and Propylparaben in a Pharmaceutical Gel.
2010-07
(Biphenyl-4-yl)(phen-yl)methanone.
2010-03-27
Otomycosis: Diagnosis and treatment.
2010-03-04
Association of high-dose bifonazole administration during early pregnancy and severe limb reduction defects in the newborn.
2010-03
Efficacy of intrasinusal administration of bifonazole cream alone or in combination with enilconazole irrigation in canine sino-nasal aspergillosis: 17 cases.
2010-02
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
2010-02
Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
2009-11
Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay.
2009-09-14
In vitro susceptibility of nondermatophyte molds isolated from onycomycosis to antifungal drugs.
2009-08
Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning.
2009-06-09
Calcium fingerprints induced by calmodulin interactors in eukaryotic cells.
2009-06
[Muscle effects due to the association of simvastatin and bifonazole cream].
2009-04-21
[Usefulness of bifonazole for treatment of tinea pedis in the 20th year after approval].
2009-04
Determination of azole antifungal medicines using zero-order and derivative UV spectrophotometry.
2009-02-21
Fungal nail infections: diagnosis and management.
2009-02
Chemical composition of essential oils of Thymus and Mentha species and their antifungal activities.
2009-01-07
[Cutaneous infection caused by Alternaria alternata in an immunocompetent host].
2009-01
[Guidelines for diagnosis and treatment of mucocutaneous candidiasis].
2009
In vitro antifungal activities of luliconazole, a new topical imidazole.
2009
Antifungal activity of the essential oil of Thymus vulgaris L. and thymol on experimentally induced dermatomycoses.
2008-12
Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes.
2008-08-01
In vitro antifungal activity of sertaconazole nitrate against recent isolates of onychomycosis causative agents.
2008-08
1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
2008-07-10
Thermodynamic fidelity of the mammalian cytochrome P450 2B4 active site in binding substrates and inhibitors.
2008-03-14
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
2008-02-01
In vivo methods for the assessment of topical drug bioavailability.
2008-01
Tinea nigra by Hortaea werneckii, a report of 22 cases from Mexico.
2008
Topical fenticonazole in dermatology and gynaecology: current role in therapy.
2008
Generalized tinea corporis due to Trichophyton rubrum in ichthyosis vulgaris.
2007-09
Enantioselective separation of azole compounds by EKC. Reversal of migration order of enantiomers with CD concentration.
2007-08
Seborrhoeic dermatitis.
2007-07-01
Decreased susceptibility to antifungals in respiratory-deficient Kluyveromyces lactis mutants.
2007
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
2006-12
Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles.
2006-11-10
Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme.
2006-11-01
Enantiomeric resolution of bifonazole by supercritical fluid chromatography.
2006-07
In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses.
2006-06
A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis.
2006-05
MgSlt2, a cellular integrity MAP kinase gene of the fungal wheat pathogen Mycosphaerella graminicola, is dispensable for penetration but essential for invasive growth.
2006-04
Simultaneous determination of bifonazole and tinctures of calendula flower in pharmaceutical creams by reversed-phase liquid chromatography.
2006-03-11
Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.
2006-03-03
Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation.
2006-02-15
What defines the quality of patient care in tinea pedis?
2006-02
High-performance thin-layer chromatography determination of some antimycotic imidazole derivatives and preservatives in medicinal creams and a gel.
2006-01-03
Athlete's foot.
2005-12
Chemical avulsion with urea nail lacquer.
2002-12
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans.
1992-05
Patents

Sample Use Guides

Bifonazole 1% w/w Cream. The cream should be applied thinly and evenly to the affected areas once daily, preferably at night before going to bed, and rubbed in gently. Treatment should be continued for 2-3 weeks, depending on the type of infection.
Route of Administration: Transdermal
In Vitro Use Guide
Concentrations of less than or equal to 5 ug/ml bifonazole have a fungicidal effect on dermatophytes, and a MIC value of less than or equal to 0.25 ug/ml has a maximal effect on Torulopsis glabrata. In ng concentrations bifonazole is effective on proliferating dermatophytes and pseudomycelia of Candida albicans.
Name Type Language
BIFONAZOLE
EP   INCI   INN   MART.   MI   USAN   WHO-DD  
INCI   INN   USAN  
Official Name English
MYCOSPOR
Preferred Name English
(±)-1-(P,.ALPHA.-DIPHENYLBENZYL)IMIDAZOLE
Common Name English
BIFONAZOLE [MART.]
Common Name English
bifonazole [INN]
Common Name English
BIFONAZOLE [EP MONOGRAPH]
Common Name English
Bifonazole [WHO-DD]
Common Name English
BAY-H-4502
Code English
1H-IMIDAZOLE, 1-((1,1'-BIPHENYL)-4-YLPHENYLMETHYL)-, (±)-
Systematic Name English
BIFONAZOLE [JAN]
Common Name English
NSC-758954
Code English
BIFONAZOLE [MI]
Common Name English
BIFONAZOLE [EP IMPURITY]
Common Name English
BAY H 4502
Code English
BIFONAZOLE [USAN]
Common Name English
D01AC10
Code English
1-((4-BIPHENYLYL)-PHENYLMETHYL)-1H-IMIDAZOLE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
WHO-VATC QD01AC60
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
WHO-VATC QD01AC10
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
WHO-ATC D01AC10
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
WHO-ATC D01AC60
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
Code System Code Type Description
INN
4887
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
262-336-6
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
EVMPD
SUB05831MIG
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
MESH
C036596
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
RXCUI
19295
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY RxNorm
CAS
60628-96-8
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
NSC
758954
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID9045631
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
CHEBI
31286
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
WIKIPEDIA
BIFONAZOLE
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
NCI_THESAURUS
C87450
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
DRUG BANK
DB04794
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
PUBCHEM
2378
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL277535
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
MERCK INDEX
m2486
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY Merck Index
SMS_ID
100000091948
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
FDA UNII
QYJ305Z91O
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY
DRUG CENTRAL
370
Created by admin on Wed Apr 02 09:30:11 GMT 2025 , Edited by admin on Wed Apr 02 09:30:11 GMT 2025
PRIMARY